8,233 results match your criteria Journal of Controlled Release[Journal]


Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs.

J Control Release 2019 Feb 19. Epub 2019 Feb 19.

Institute for Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany. Electronic address:

Stimuli-responsive polymer-drug conjugates (PDCs) provide promising approaches in anticancer treatment. Here, we report the synthesis and biological evaluation of PDCs made of the highly potent antimitotic agent monomethyl auristatin E conjugated to dendritic polyglycerol and dendritic polyglycerol sulfate via a reductively cleavable, self-immolative disulfide linker. Cell viability assays with the human cancer cell lines A549 (lung carcinoma) and HeLa (cervix carcinoma) revealed that the drug's cytotoxicity was reduced by conjugation to the polymers, with the sulfated conjugates being more effective than the non-sulfated ones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.035DOI Listing
February 2019

Pharmacokinetics and tissue distribution of neurotrophin 3 after intracochlear delivery.

J Control Release 2019 Feb 18. Epub 2019 Feb 18.

Bionics Institute, Melbourne, Australia; University of Melbourne, Department of Medical Bionics, Melbourne, Australia; University of Melbourne, Department of Otolaryngology, Melbourne, Australia.

Neurotrophin therapy has potential to reverse some forms of hearing loss. However, cochlear pharmacokinetic studies are challenging due to small fluid volumes. Here a radioactive tracer was used to determine neurotrophin-3 retention, distribution and clearance after intracochlear administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.018DOI Listing
February 2019

Poly(ethylene glycol)-block-poly(d,l-lactic acid) micelles containing oligo(lactic acid)-paclitaxel prodrug: In Vivo conversion and antitumor efficacy.

J Control Release 2019 Feb 18. Epub 2019 Feb 18.

Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI 53705-2222, USA. Electronic address:

Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles affect drug solubilization, and a paclitaxel (PTX) loaded-PEG-b-PLA micelle (PTX-PM) is approved for cancer treatment due to injection safety and dose escalation (Genexol-PM®) compares to Taxol®. However, PTX-PM is unstable in blood, has rapid clearance, and causes dose-limiting toxicity. We have synthesized a prodrug for PTX (7-OH), using oligo(lactic acid) as a novel pro-moiety (o(LA)-PTX) specifically for PEG-b-PLA micelles, gaining higher loading and slower release of o(LA)-PTX over PTX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.017DOI Listing
February 2019

Continuous alternative to freeze drying: Manufacturing of cyclodextrin-based reconstitution powder from aqueous solution using scaled-up electrospinning.

J Control Release 2019 Feb 16;298:120-127. Epub 2019 Feb 16.

Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), Műegyetem rakpart 3, Budapest H-1111, Hungary.

The aims of this study were to evaluate electrospinning as a continuous alternative to freeze drying in the production of a reconstitution injection dosage form, and to prove that aqueous electrospinning can be realized with a high production rate at room temperature. High-speed electrospinning with a novel continuous cyclone collection was used to manufacture a formulation of the poorly water-soluble antifungal voriconazole (VOR) with sulfobutylether-β-cyclodextrin (SBE-β-CD). The freeze-dried, marketed product of this drug substance, Vfend® also contains SBE-β-CD as excipient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.019DOI Listing
February 2019

Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma.

J Control Release 2019 Feb 15. Epub 2019 Feb 15.

Departments of Pediatrics, Physiology and Pharmacology, University of Montréal, Montréal, QC, Canada. Electronic address:

Melphalan is an efficient chemotherapeutic agent that is currently used to treat retinoblastoma (Rb); however, the inherent risk of immunogenicity and the hazardous integration of this drug in healthy cells is inevitable. MicroRNAs are short non-coding single-stranded RNAs that affect a vast range of biological processes. Previously, we focused on the regulatory role of miR-181a during cancer development and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.014DOI Listing
February 2019

Albumin-binding Auristatin prodrugs for long-term tumor regressions.

Authors:
Kinam Park

J Control Release 2019 Feb;296:258

Purdue University, Biomedical Engineering and Pharmaceutics, West Lafayette, IN 47907, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.001DOI Listing
February 2019

Two-dimensional cancer theranostic nanomaterials: Synthesis, surface functionalization and applications in photothermal therapy.

J Control Release 2019 Feb 13. Epub 2019 Feb 13.

SRM Research Institute, SRM Institute of Science and Technology, Kattankulathur 603203, Kanchipuram, India; Department of Physics and Nanotechnology, SRM Institute of Science and Technology, Kattankulathur 603203, Kanchipuram, India. Electronic address:

In recent years, novel two-dimensional (2D) nanomaterials are of great interest for diverse potential applications such as device fabrication, energy storage, sensing and theranostics because of their superlative physical features namely, large surface area, minimal thickness, tunable composition and easier surface modification methods. Rapid exploration in design and fabrication of 2D nano-structures have opened new avenue for cancer theranostics as it can encapsulate group of cancer cells and inflict major damage with great specificity in a non-invasive manner. Among the reported 2D materials such as graphene and its derivatives, metallic compounds, transition metal dichalcogenides (TMDC), black phosphorous and MXenes (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.015DOI Listing
February 2019
1 Read

Sequential activation of anticancer therapy triggered by tumor microenvironment-selective imaging.

J Control Release 2019 Feb 13;298:110-119. Epub 2019 Feb 13.

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Electronic address:

The combination of imaging and anticancer therapy has recently emerged as a promising strategy. However, nonspecific imaging signals and distribution of anticancer drugs at normal tissues limit the specificity of the combination therapy. To overcome the challenges, we designed a system which can selectively visualize cancer tissues and initiate the subsequent action of therapeutic molecules in tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.012DOI Listing
February 2019
2 Reads

Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.

J Control Release 2019 Feb 13;298:128-141. Epub 2019 Feb 13.

Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8224, St. Louis, MO 63110, USA; Department of Radiation Oncology, Biologic Therapeutics Center, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8224, St. Louis, MO 63110, USA. Electronic address:

Hemophilia B (HB) is a life-threatening inherited disease caused by mutations in the FIX gene, leading to reduced protein function and abnormal blood clotting. Due to its monogenic nature, HB is one of the primary targets for gene therapy. Indeed, successful correction of HB has been shown in clinical trials using gene therapy approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.009DOI Listing
February 2019
1 Read

Mechanistic insights into the pH-dependent membrane peptide ATRAM.

J Control Release 2019 Feb 11;298:142-153. Epub 2019 Feb 11.

Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States. Electronic address:

pH-responsive peptides are promising therapeutic molecules that can specifically target the plasma membrane in the acidified extracellular medium that bathes cells in tumors. We designed the acidity-triggered rational membrane (ATRAM) peptide to have a pH-responsive membrane interaction. At physiological pH, ATRAM binds to the membrane surface in a largely unstructured conformation, while in acidic conditions it inserts into lipid bilayers forming a transmembrane helix. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.010DOI Listing
February 2019
1 Read

PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.

J Control Release 2019 Feb 11. Epub 2019 Feb 11.

Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA; Siteman Cancer Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA. Electronic address:

Targeted molecular imaging allows specific visualization and monitoring of tumors. Cancer-specific peptides have been developed for imaging and therapy. Peptides that specifically target cancer have several advantages including, ease of synthesis, low antigenicity, and enhanced diffusion into tissues. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193008
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.02.008DOI Listing
February 2019
4 Reads

Involvement of planned cell death of necroptosis in cancer treatment by nanomaterials: Recent advances and future perspectives.

J Control Release 2019 Feb 11. Epub 2019 Feb 11.

Department of Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Electronic address:

With the expansion of the field of nanomedicine, the use of nanomaterials in cancer treatment has raised questions about their safety and unpredictable adverse effects. To date, the hazardous effects of nanomaterials have been investigated based on cell survival and cellular functionality, such as membrane integrity, mitochondrial activity and cell morphology. It is increasingly noted that more detailed analysis of regulated cell death pathways (RCD) triggered by nanomaterials is essential to understand their full mechanism of action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.007DOI Listing
February 2019

Light-triggered release of photocaged therapeutics - Where are we now?

J Control Release 2019 Feb 8;298:154-176. Epub 2019 Feb 8.

3B's Research Group - Biomaterials, Biodegradable and Biomimetic, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark 4805-017 Barco, Guimarães, Portugal; ICVS/3B's PT Government Associated Laboratory, Braga/Guimarães, Portugal; The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark 4805-017 Barco, Guimarães, Portugal.

The current available therapeutics face several challenges such as the development of ideal drug delivery systems towards the goal of personalized treatments for patients benefit. The application of light as an exogenous activation mechanism has shown promising outcomes, owning to the spatiotemporal confinement of the treatment in the vicinity of the diseased tissue, which offers many intriguing possibilities. Engineering therapeutics with light responsive moieties have been explored to enhance the bioavailability, and drug efficacy either in vitro or in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.006DOI Listing
February 2019

Nanoencapsulation of carotenoids within lipid-based nanocarriers.

J Control Release 2019 Feb 7;298:38-67. Epub 2019 Feb 7.

Faculty of Food Science and Technology, Gorgan University of Agricultural Sciences and Natural Resources, Gorgan, Iran. Electronic address:

Carotenoids, as promising functional components in human diet, are gaining immense importance todays. Apart from their pivotal importance in photosynthetic organisms or as natural pigments, they are typically referred to as health-promotional ingredients, which offer several beneficial attributes. However, their sensitivity against environmental and process stresses, low-water solubility, as well as low-bioavailability are the most shortfalls restricting pharmaceutical/food carotenoid applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.005DOI Listing
February 2019
1 Read

Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination.

J Control Release 2019 Feb 6;298:12-26. Epub 2019 Feb 6.

DBV Technologies, Montrouge, France.

The skin is an immune organ comprised of a large network of antigen-presenting cells such as dendritic cells, making it an attractive target for the development of new vaccines and immunotherapies. Recently, we developed a new innovative and non-invasive vaccination method without adjuvant based on epicutaneous vaccine patches on which antigen forms a dry deposit. Here we describe in mice a method for potentiating the efficacy of our epicutaneous vaccination approach using a minimally invasive and epidermis-limited skin preparation based on laser-induced micro-perforation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.004DOI Listing
February 2019

Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments.

J Control Release 2019 Feb 4. Epub 2019 Feb 4.

Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.

Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is recalcitrant to antibiotic therapy. There also is currently no licensed vaccine for this potentially fatal pathogen, further highlighting the requirement for better therapeutics to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome to entrap already- licensed antibiotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.002DOI Listing
February 2019

Congruent release of drug and polymer: A "sweet spot" in the dissolution of amorphous solid dispersions.

J Control Release 2019 Feb 4;298:68-82. Epub 2019 Feb 4.

Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA. Electronic address:

Liquid-liquid phase separation (LLPS) occurs following amorphous solid dispersion (ASD) dissolution when the drug concentration exceeds the "amorphous solubility", and is emerging as an important characteristic of formulations that may enhance the oral bioavailability of poorly soluble drugs. The purpose of this research was to identify criteria that impact the rate and extent of drug release and hence the occurrence or not of LLPS upon ASD dissolution. Specifically, the effect of drug log P, phase behavior of the hydrated but undissolved ASD matrix and the relative dissolution rates of drug and polymer were studied as a function of drug loading, using nilvadipine (Nil) (ClogP = 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.039DOI Listing
February 2019

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES.

J Control Release 2019 Feb 4;298:1-11. Epub 2019 Feb 4.

School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK. Electronic address:

Antiretroviral-releasing vaginal rings are at the forefront of ongoing efforts to develop microbicide-based strategies for prevention of heterosexual transmission of the human immunodeficiency virus (HIV). However, traditional ring designs are generally only useful for vaginal administration of relatively potent, lipophilic, and small molecular weight drug molecules that have sufficient permeability in the non-biodegradable silicone elastomer or thermoplastic polymers. Here, we report a novel, easy-to-manufacture 'exposed-core' vaginal ring that provides sustained release of the protein microbicide candidate 5P12-RANTES, an experimental chemokine analogue that potently blocks the HIV CCR5 coreceptor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.02.003DOI Listing
February 2019

Multi-functional peptide-modified liposomes for treatment of glioma.

Authors:
Kinam Park

J Control Release 2018 Nov;289:171

Purdue University, Biomedical Engineering and Pharmaceutics, West Lafayette, IN 47907, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2018.10.023DOI Listing
November 2018

Therapeutic vitamin delivery: Chemical and physical methods with future directions.

J Control Release 2019 Jan 29;298:83-98. Epub 2019 Jan 29.

Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. Electronic address:

Vitamins are a diverse group of "life nourishing" molecules that are essential for proper childhood development, and for maintaining health throughout adulthood into old age. Vitamin supplementation is an important strategy for reducing the severe and chronic effects of malnutrition in subsets of the population of the developing world. Additionally, the precise role of many vitamins in certain conditions, including cancer and cardiovascular disease, remains an area of active research, although guidelines for vitamin supplementation in otherwise adequately nourished populations remain controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.038DOI Listing
January 2019

Intestinal iontophoresis from mucoadhesive patches: a strategy for oral delivery.

J Control Release 2019 Jan 29;297:71-78. Epub 2019 Jan 29.

School of Engineering and Applied Sciences, Wyss Institute, Harvard University, Cambridge, MA 02138, USA. Electronic address:

Biologics have limited permeability across the intestine and are prone to degradation in the acidic-proteolytic milieu of the gastrointestinal tract, leading to poor oral bioavailability. Iontophoresis is a promising technology that can substantially improve transport of drugs across biological barriers and has been particularly explored for skin. In this study, we investigated whether iontophoresis across the intestine can be utilized to improve oral insulin transport. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.037DOI Listing
January 2019

Optimal nanoparticle design for effective transport through the blood-brain barrier.

Authors:
Kinam Park

J Control Release 2019 Feb;295:290

Purdue University, Biomedical Engineering and Pharmaceutics, West Lafayette, IN 47907, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.024DOI Listing
February 2019

Thermosensitive nanocomposite gel for intra-tumoral two-photon photodynamic therapy.

J Control Release 2019 Jan 28;298:99-109. Epub 2019 Jan 28.

Department of Chemistry, Anhui University, Hefei, PR China; Department of Chemistry, University College London, UK; Department of Chemical Engineering, University College London, UK. Electronic address:

We propose here a new approach to achieve intratumoral near-infrared (NIR) two-photon photodynamic therapy (PDT). We established a composite micellar thermosensitive hydrogel made of clinically approved methoxy poly(ethylene glycol)-polylactide copolymer (mPEG-PDLLA) and Pluronic (F127). The mPEG-PDLLA form micelles that can be loaded with two-photon absorption compound (T1) and photosensitizer (PS), The F127 micelles are liquid at room temperature and while forming an hydrogel at body temperature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.019DOI Listing
January 2019
2 Reads
7.705 Impact Factor

Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity.

J Control Release 2019 Jan 25;297:48-59. Epub 2019 Jan 25.

Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, United States; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239, United States. Electronic address:

Viral gene therapy is a means of delivering genes to replace malfunctioning ones, to kill cancer cells, or to correct genetic mutations. This technology is emerging as a powerful clinical tool; however, it is still limited by viral tropism, uptake and clearance by the liver, and most importantly an immune response. To overcome these challenges, we sought to merge the robustness of viral gene expression and the versatility of nanoparticle technology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.034DOI Listing
January 2019
7.705 Impact Factor

A nanoliter resolution implantable micropump for murine inner ear drug delivery.

J Control Release 2019 Jan 25;298:27-37. Epub 2019 Jan 25.

Department of Microsystems Engineering, Rochester Institute of Technology, Rochester, NY, USA. Electronic address:

Advances in protective and restorative biotherapies have created new opportunities to use site-directed, programmable drug delivery systems to treat auditory and vestibular disorders. Successful therapy development that leverages the transgenic, knock-in, and knock-out variants of mouse models of human disease requires advanced microsystems specifically designed to function with nanoliter precision and with system volumes suitable for implantation. Here we present results for a novel biocompatible, implantable, scalable, and wirelessly controlled peristaltic micropump. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.032DOI Listing
January 2019

Adhesive nanoparticles with inflammation regulation for promoting skin flap regeneration.

J Control Release 2019 Jan 25;297:91-101. Epub 2019 Jan 25.

Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, PR China.. Electronic address:

Local drug delivery systems have become an important field of research as locally administration of medications may overcome most of the drawbacks associated with systemic drugs. Still, to assure continuous drug release and therapeutic drug levels, keeping the delivered drug in target area remains a physiological challenge. The aim of this study was to develop novel multipotent flap-protective adhesive mangiferin (MF)-loaded liposomes (A-MF-Lip), bioinspired in mussel architecture, for the promotion of random skin flap regeneration. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193005
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.01.031DOI Listing
January 2019
3 Reads

Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.

J Control Release 2019 Jan 25;297:3-13. Epub 2019 Jan 25.

Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, 501 S. Preston St., Louisville, KY 40202, United States; Department of Microbiology and Immunology, University of Louisville School of Medicine, United States. Electronic address:

The interaction of the periodontal pathogen Porphyromonas gingivalis (Pg) with commensal streptococci promotes Pg colonization of the oral cavity. Previously, we demonstrated that a peptide (BAR) derived from Streptococcus gordonii (Sg) potently inhibited adherence of Pg to streptococci and reduced Pg virulence in a mouse model of periodontitis. Thus, BAR may represent a novel therapeutic to control periodontitis by preventing Pg colonization of the oral cavity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.036DOI Listing
January 2019

Local delivery of stabilized chondroitinase ABC degrades chondroitin sulfate proteoglycans in stroke-injured rat brains.

J Control Release 2019 Jan 25;297:14-25. Epub 2019 Jan 25.

Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, Ontario M5S 3E5, Canada; Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, 160 College Street, Toronto, Ontario M5S 3E1, Canada; Institute of Biomaterials and Biomedical Engineering, 164 College Street, Toronto, Ontario M5S 3G9, Canada; Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada. Electronic address:

Central nervous system (CNS) injuries, such as stroke and spinal cord injuries, result in the formation of a proteoglycan-rich glial scar, which acts as a barrier to axonal regrowth and limits the regenerative capacity of the CNS. Chondroitinase ABC (ChABC) is a potent bacterial enzyme that degrades the chondroitin sulfate proteoglycan (CSPG) component of the glial scar and promotes tissue recovery; however, its use is significantly limited by its inherent instability at physiological temperatures. Here, we demonstrate that ChABC can be stabilized using site-directed mutagenesis and covalent modification with poly(ethylene glycol) chains (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.033DOI Listing
January 2019
7.705 Impact Factor

Injectable thermosensitive hydrogel systems based on functional PEG/PCL block polymer for local drug delivery.

J Control Release 2019 Jan 23;297:60-70. Epub 2019 Jan 23.

Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA. Electronic address:

Injectable in situ thermosensitive hydrogels have potential applications in tissue engineering and drug delivery. The hydrogel formulations exist as aqueous solutions at room temperature but rapidly solidify into gels at 37 °C in situ, making them highly suitable for administering drugs in a minimally invasive manner to the target organ(s). The hydrogel formed with nanoparticles assembled with amphiphilic polymer blocks of polyethyleneglycol (PEG) and biodegradable polycaprolactone (PCL) have been tested as platforms for targeted and sustained drug delivery, and have shown encouraging results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.026DOI Listing
January 2019
2 Reads

Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals.

J Control Release 2019 Jan 23;297:39-47. Epub 2019 Jan 23.

Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY 14260, USA. Electronic address:

Chemophototherapy (CPT) merges photodynamic therapy with chemotherapy and can substantially enhance drug delivery. Using a singular liposomal formulation for CPT, we describe a semi-mechanistic pharmacokinetic-pharmacodynamic (PK/PD) model to investigate observed antitumor effects. Long-circulating, sterically-stabilized liposomes loaded with doxorubicin (Dox) stably incorporate small amounts of a porphyrin-phospholipid (PoP) photosensitizer in the bilayer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.030DOI Listing
January 2019
3 Reads

The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor.

J Control Release 2019 Feb 22;296:250-257. Epub 2019 Jan 22.

Groningen Research Institute of Pharmacy, Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands. Electronic address:

Rho kinase activity in hepatic stellate cells (HSCs) is associated with activation, transformation and contraction of these cells, leading to extracellular matrix production and portal hypertension in liver cirrhosis. Inhibition of rho kinase activity can reduce these activities, but may also lead to side effects, for instance systemic hypotension. This can be circumvented by liver-specific delivery of a rho kinase inhibitor to effector cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2018.12.039DOI Listing
February 2019
2 Reads

Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.

J Control Release 2019 Feb 22;296:232-240. Epub 2019 Jan 22.

Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Electronic address:

Glucocorticoids are the cornerstone in the clinic for treatment of hematological malignancies, including multiple myeloma. Nevertheless, poor pharmacokinetic properties of glucocorticoids require high and frequent dosing with the off-target adverse effects defining the maximum dose. Recently, nanomedicine formulations of glucocorticoids have been developed that improve the pharmacokinetic profile, limit adverse effects and improve solid tumor accumulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.028DOI Listing
February 2019
5 Reads

Recent advances in topical delivery of flavonoids: A review.

J Control Release 2019 Feb 22;296:190-201. Epub 2019 Jan 22.

Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L.Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India. Electronic address:

Flavonoids are one of the vital classes of bioactive chemicals, abundantly found in plants. These are natural polyphenolic compounds derived from plant metabolites. Their lipophilic nature and poor solubility lead to variable and limited oral bioavailability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.029DOI Listing
February 2019

Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation.

J Control Release 2019 Feb 23;296:150-161. Epub 2019 Jan 23.

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Guangzhou 510275, PR China. Electronic address:

Basal-like breast cancer exhibits a triple-negative phenotype and has a poor prognosis, even with traditional chemical and anti-human epidermal growth factor receptor (HER) treatments. However, the high mutation rate of this obstinate cancer type renders it suitable for immunotherapy. Photothermal therapy (PTT) is a high-efficiency method for inducing tumor neoantigen release in situ, which has great potential for use in cancer immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.027DOI Listing
February 2019

Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals.

J Control Release 2019 Feb 21;296:162-178. Epub 2019 Jan 21.

Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary.

In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193004
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.01.023DOI Listing
February 2019
5 Reads

Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers.

J Control Release 2019 Feb 21;296:225-231. Epub 2019 Jan 21.

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, NJ 08854, United States. Electronic address:

Cystic fibrosis (CF), a most deadly genetic disorder, is caused by mutations of CF transmembrane receptor (CFTR) - a chloride channel present at the surface of epithelial cells. In general, two steps have to be involved in treatment of the disease: correction of cellular defects and potentiation to further increase channel opening. Consequently, a combinatorial simultaneous treatment with two drugs with different mechanisms of action, lumacaftor and ivacaftor, has been recently proposed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.025DOI Listing
February 2019
1 Read

Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma.

J Control Release 2019 Jan 18;297:26-38. Epub 2019 Jan 18.

Pharmaceutical Innovation in Ophthalmology (InnOftal), Research Group (UCM 920415), Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain; Red Temática de Investigación Cooperativa Sanitaria en Enfermedades Oculares (Oftared) e Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), United Kingdom. Electronic address:

Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of irreversible blindness globally and for which intraocular pressure is the only modifiable risk factor. Although neuroprotective therapies have been suggested to have therapeutic potential, drug delivery for the treatment of ocular disorders such as glaucoma remains an unmet clinical need, further complicated by poor patient compliance with topically applied treatments. In the present study we describe the development of multi-loaded PLGA-microspheres (MSs) incorporating three recognised neuroprotective agents (dexamethasone (DX), melatonin (MEL) and coenzyme Q10 (CoQ10)) in a single formulation (DMQ-MSs) to create a novel sustained-release intraocular drug delivery system (IODDS) for the treatment of glaucoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.012DOI Listing
January 2019
4 Reads

Editorial for 15th European symposium on controlled drug delivery.

J Control Release 2019 Jan 19;297:1-2. Epub 2019 Jan 19.

Department of Biomolecular Nanotechnology, MESA+ Institute for Nanotechnology and TechMed Institute for Health and Biomedical Technologies, Faculty of Science and Technology, University of Twente, P.O. Box 217, 7500, AE, Enschede, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.021DOI Listing
January 2019
1 Read

Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies.

J Control Release 2019 Feb 18;296:114-139. Epub 2019 Jan 18.

Department of Pharmaceutics, Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390001, India. Electronic address:

Hematological cancers are a group of malignancies affecting human hematopoietic and lymphoid tissues. Although the patients respond to treatment regimen during initial phases, the hematoma tumor heterogeneity results in the presence of some minimal disease residue thereby exhibiting remission, relapses or refractoriness in disease conditions leading to poor overall survival period. The current therapeutic standard practices involve blending of conventional agents with novel targeting agents or immune-therapeutics in a cocktail to effectively reap the benefits of drugs acting through multiple signaling pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.011DOI Listing
February 2019
9 Reads

Standardization of research methods employed in assessing the interaction between metallic-based nanoparticles and the blood-brain barrier: Present and future perspectives.

J Control Release 2019 Feb 18;296:202-224. Epub 2019 Jan 18.

Bernal Institute, University of Limerick, Limerick, Ireland; School of Engineering, University of Limerick, Limerick, Ireland; Health Research Institute, (HRI), University of Limerick, Limerick, Ireland; Solid State Pharmaceutical Centre, University of Limerick, Limerick, Ireland. Electronic address:

Treating diseases of the central nervous system (CNS) is complicated by the presence of the blood-brain barrier (BBB), a semipermeable boundary layer protecting the CNS from toxins and homeostatic disruptions. However, this layer also excludes almost 100% of therapeutics, impeding the treatment of CNS diseases. The advent of nanoparticles, in particular metallic-based nanoparticles, presents the potential to overcome this barrier and transport drugs into the CNS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.022DOI Listing
February 2019
3 Reads
7.705 Impact Factor

Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for "on-demand" drug delivery.

J Control Release 2019 Feb 19;296:93-106. Epub 2019 Jan 19.

Department of Hematology and Research Laboratory of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China. Electronic address:

At present, chemotherapy remains to be one of the most important therapeutic approaches for malignant tumors. The tumor microenvironment(TME)-responsive intelligent drug delivery systems are still the hot research topics in delivering chemotherapeutic drugs. Camptothecin (CPT) possesses very strong antitumor activities, but its clinical application is hindered by its poor water-solubility and serious toxic side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.016DOI Listing
February 2019
2 Reads

Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration.

J Control Release 2019 Feb 17;296:140-149. Epub 2019 Jan 17.

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, United States. Electronic address:

As one of the leading causes of central vision loss in elderly population, worldwide cases of age-related macular degeneration (AMD) have seen a dramatic increase over the past several years. Treatment regimens for AMD, especially with biological agents, are complicated due to anatomical and physiological barriers, as well as administration of high doses and frequent regimens. Some clinical examples include monthly intravitreal administration of anti-VEGF antibody ranibizumab (Lucentis®) from Genentech and aflibercept (Eylea®) from Regeneron Pharmaceuticals. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193002
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.01.007DOI Listing
February 2019
3 Reads

Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.

J Control Release 2019 Feb 17;296:68-80. Epub 2019 Jan 17.

Department of Ophthalmology, The Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, USA; Center for Nanomedicine, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, 400 North Broadway, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA; Department of Biomedical Engineering, The Johns Hopkins University, Baltimore, MD 21231, USA; Departments of Oncology, Neurosurgery, and Pharmacology & Molecular Sciences, The Johns Hopkins University, Baltimore, MD 21231, USA. Electronic address:

Noninfectious uveitis is a potentially blinding ocular condition that often requires treatment with corticosteroids to prevent inflammation-related ocular complications. Severe forms of uveitis such as panuveitis that affects the whole eye often require a combination of topical and either regional or systemic corticosteroid. Regional corticosteroids are currently delivered inside the eye by intravitreal injection (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.018DOI Listing
February 2019
5 Reads
7.705 Impact Factor

Probing the mechanism of drug release from liposomes.

Authors:
Kinam Park

J Control Release 2019 Jan;294:390

Purdue University, Biomedical Engineering and Pharmaceutics, West Lafayette, IN 47907, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.003DOI Listing
January 2019

Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances.

J Control Release 2019 Jan 16;297:79-90. Epub 2019 Jan 16.

Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, London SE1 9NH, United Kingdom. Electronic address:

Tumour-specific, immuno-based therapeutic interventions can be considered as safe and effective approaches for cancer therapy. Exploitation of nano-vaccinology to intensify the cancer vaccine potency may overcome the need for administration of high vaccine doses or additional adjuvants and therefore could be a more efficient approach. Carbon nanotube (CNT) can be described as carbon sheet(s) rolled up into a cylinder that is nanometers wide and nanometers to micrometers long. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193003
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.01.017DOI Listing
January 2019
7 Reads

The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug.

J Control Release 2019 Feb 16;296:241-249. Epub 2019 Jan 16.

Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergent Science and Technology, Seoul National University, Seoul 08826, South Korea; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, South Korea. Electronic address:

The selective targeting of cytotoxic agents to a tumor has shown limited success by difficulties in identifying the appropriate target molecules, and more importantly, by the phenotypically dynamic nature of the tumor cells and intratumoral heterogeneity. In an attempt to overcome these issues and efficiently deliver cytotoxic drugs to the tumor, we previously reported a strategy termed radiation-induced apoptosis-targeted chemotherapy (RIATC), which utilizes the radiotherapy for intentionally triggering the caspase-3 and in situ amplification of tumor apoptosis by caspase-3 activated prodrug. Herein, we propose an advanced form of RIATC prodrug, AP1-DEVD-S-DOX, that could more actively target to the ligands of radiation-induced tumor cells, which could accumulate more prodrugs, thereby allowing more effective in situ activation and amplification of tumor apoptosis, comparing to RIATC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193003
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.01.020DOI Listing
February 2019
10 Reads

Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis.

J Control Release 2019 Feb 16;296:179-189. Epub 2019 Jan 16.

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Univ. Paris-Saclay, 92290 Châtenay-Malabry, France. Electronic address:

Rheumatoid arthritis (RA) is a prevalent autoimmune disease characterized by joint inflammation, bone and cartilage erosion. The use of glucocorticoids in the treatment of RA is hampered by significant side effects induced by their unfavorable pharmacokinetics. Delivering glucocorticoids by means of nanotechnologies is promising but the encapsulation of highly crystalline and poorly water-soluble drugs results in poor loading and low stability. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01683659193003
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2019.01.015DOI Listing
February 2019
43 Reads

Aligned microchannel polymer-nanotube composites for peripheral nerve regeneration: Small molecule drug delivery.

J Control Release 2019 Feb 15;296:54-67. Epub 2019 Jan 15.

Department of Biomedical Engineering, University of Connecticut, Storrs, CT, USA; Department of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA. Electronic address:

Peripheral nerve injury accounts for roughly 2.8% of all trauma patients with an annual cost of 7 billion USD in the U.S. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379151PMC
February 2019
1 Read

KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.

J Control Release 2019 Feb 15;296:40-53. Epub 2019 Jan 15.

School of Pharmaceutical Sciences and Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing 100084, China. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC) is a dominantly (~95%) KRAS-mutant cancer that has extremely poor prognosis, in part this is due to its strong intrinsic resistance towards almost all therapeutic agents. PDAC relies heavily on KRAS-transformed metabolism, including enhanced macropinocytosis and catabolism of extracellular albumin, to maintain its proliferation and progression. However, it has yet to be validated that whether such transformed metabolism could be exploited for the drug delivery to open therapeutic windows of cytotoxic agents in KRAS-mutant PDAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.014DOI Listing
February 2019

Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.

J Control Release 2019 Feb 11;296:81-92. Epub 2019 Jan 11.

CytRx Drug Discovery Branch, Centurion Biopharma Corporation, Engesserstr. 4, Freiburg 79108, Germany. Electronic address:

Auristatins are a class of highly cytotoxic tubulin-disrupting peptides, which have shown limited therapeutic effect as free agents in clinical trials. In our continuing effort to develop acid-sensitive albumin-binding anticancer drugs exploiting circulating serum albumin as the drug carrier, we investigated the highly toxic drug payload auristatin E to assess whether the corresponding albumin-binding prodrugs were a viable option for achieving significant and concomitant tolerable antitumor activity. To achieve our goal, we developed a new aromatic maleimide-bearing linker (Sulf07) which enhanced both water solubility and stability of the prodrugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2019.01.010DOI Listing
February 2019
2 Reads